In cell models, DYRK1A knockdown or enzymatic inhibition reduced the proliferation of HNSCC cell lines [85], luminal/HER2 breast cancer [87] or PDAC [68], as well as impaired the self-renewal capacity of GBM cells [66] and compromised ovarian cancer spheroid cell viability [79]. Here, DYRK1A is linked to breast cancer.